Shaanxi Kanghui Pharmaceutical CO., LTD.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shaanxi Kanghui Pharmaceutical Co., Ltd. (stock abbreviation: "Kanghui Pharmaceutical", stock code: 603139) is a national high-tech enterprise that integrates drug research, development, production, and sales, and a national intellectual property advantage enterprise. The company has 4 subsidiaries and 3 drug production bases, with a total of 18 GMP certified preparation production lines for tablets, capsules, granules, mixtures, tea preparations, ointments, liniments, lotions, tinctures, etc. We have over 100 drug production approval numbers, including 16 exclusive products or dosage forms, 19 national invention patents, 29 varieties listed in the national medical insurance catalog, and 3 varieties listed in the national essential drug catalog, laying a solid market foundation for the company's development. The company currently has nearly 800 employees, with personnel with a college degree or above accounting for over 40% of the total number of employees. The company has a high-quality and highly specialized sales team, with a marketing network distributed in various provinces, cities, and autonomous regions across the country except for Tibet and Hainan. Its products are sold in more than 3000 medical institutions or terminal pharmacies nationwide. The company has received multiple honors at the national, provincial, and municipal levels. Its technology research and development center has been jointly recognized as a "provincial-level enterprise technology center" by the Shaanxi Provincial Department of Industry and Information Technology, Shaanxi Provincial Department of Science and Technology, and has been recognized by the Xianyang City Science and Technology Innovation Work Leading Group Office as the "Xianyang City Traditional Chinese Medicine Compound Formulation Common Key Technology Engineering Technology Research Center". The company has strong scientific research capabilities, mature pharmaceutical processes, advanced production equipment, and sophisticated testing instruments. It has a group of high-quality management talents and research and development teams, including medical and pharmaceutical experts, professors, and doctoral students. It has established an effective talent introduction, training, incentive, and assessment mechanism, forming a complete set of technology development and innovation systems that are in line with the actual situation of the company. It has established a stable cooperation relationship with famous domestic scientific research institutes, universities and institutes such as Beijing University of Traditional Chinese Medicine, China-Japan Friendship Hospital, Shaanxi Institute of Traditional Chinese Medicine, Shaanxi University of Traditional Chinese Medicine, which has improved the scientific research strength of the company and supported the continuous research and development of high-tech products. The company was listed on the Shanghai Stock Exchange on April 21, 2017 and successfully entered the capital market. In the coming years, the company will leverage the financing platform of the capital market to become one of the top pharmaceutical companies in China, becoming the most beloved by employees and respected by society. We will continue to adhere to the corporate development philosophy of "serving human health as our mission and creating social wealth as our value", adhere to the corporate culture concept of "caring for quality of life and committed to human health", advocate for the corporate spirit of "civilization, harmony, and innovation", and practice the core values of "customer first, adhering to quality, teamwork, integrity, dedication, rigor, and proactivity". Further consolidate and strengthen the company's advantages in the fields of respiratory medicine, gynecology, orthopedics, dermatology, diabetes and other medicine, and develop other new products suitable for market demand, forming a development situation that keeps pace with the mainstream medical market of traditional Chinese patent medicines and simple preparations, retail terminal market and primary medical market. |
| Headquarter | Xianyang |
| Establish Date | 12/24/2009 |
| Listed Code | 603139.SH |
| Listed Date | 4/21/2017 |
| Chairman | Wang Yanling. |
| CEO | Wang Yanling. |
| Website | www.sxkh.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
